Approval · Notice of Compliance 26262 · 2021
SYNAGIS: Notice of Compliance 26262
Issued July 9, 2021
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 26262
- Date
- July 9, 2021
- Company
- Astrazeneca Canada IncMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Admin
- Reason
- Change of Product Ownership (DIN)
Products in this notice
Medicinal ingredients
- PALIVIZUMAB 100 MG per ML
- PALIVIZUMAB 50 MG per 0.5ML